Cardiotoxicity and neurotoxicity of high-dose continuous fluorouracil as a result of degradation compounds in the drug vials

Journal of Clinical Oncology

Volumn 22, Issue 24, 2004, Pages 5022-5025

  Lukaschek, Johannes ^a   Nufer, Martin ^a   Maurer, Dominik ^a   Asanger, Maximilian ^a   Honegger, Hanspeter ^a   Widmer, Lucas ^a   Malet Martino, Myriam ^a,b   Legay, Rémi ^a,b   Martino, Robert ^a,b  

^a TRIEMLI HOSPITAL   (Switzerland)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; EXCIPIENT; FLUOROACETALDEHYDE; FLUOROMALONIC ACID SEMIALDEHYDE; FLUOROURACIL; MALONIC ACID DERIVATIVE; TROMETAMOL;

AGED; BRAIN DISEASE; CARCINOMA; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHEMISTRY; ESOPHAGUS TUMOR; FATALITY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERAMMONEMIA; LETTER; MALE; MIDDLE AGED; RECTUM TUMOR;

ACETALDEHYDE; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN DISEASES; CARCINOMA; CHEMISTRY, PHARMACEUTICAL; ESOPHAGEAL NEOPLASMS; EXCIPIENTS; FATAL OUTCOME; FEMALE; FLUOROURACIL; HUMANS; HYPERAMMONEMIA; MALE; MALONATES; MIDDLE AGED; RECTAL NEOPLASMS; TROMETHAMINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 16644396901     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2004.04.272     Document Type: Letter

References (11)

1. Becker K, Erckenbrecht JF, Haussinger D, et al: Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 57: 475-484, 1999
2. Pirzada NA, Ali II, Dafer RM: Fluorouracil-induced neurotoxicity. Ann Pharmacother 34: 35-38, 2000
3. Kuropkat C, Griem K, Clark J, et al: Severe cardiotoxicity during 5-fluorouracil chemotherapy: A case and literature report. Am J Clin Oncol 22: 466-470, 1999
4. Yeh KH, Cheng AL: High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75: 464-465, 1997
5. Koenig H, Patel A: Biochemical basis for fluorouracil neurotoxicity: The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 23: 155-160, 1970
6. Matsubara I, Kamiya J, Imai S: Cardiotoxic effects of 5-fluorouracil in the Guinea pig. Jpn J Pharmacol 30: 871-879, 1980
7. Lemaire L, Malet-Martino MC, Longo S, et al: Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil (Roche). Lancet 337: 560, 1991
8. Lemaire L, Malet-Martino MC, de Forni M, et al: Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 66: 119-127, 1992
9. Arellano M, Malet-Martino M, Martino R, et al: The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer 77: 79-88, 1998
10. Lemaire L, Malet-Martino MC, Martino R, et al: The Tris formulation of fluorouracil is more cardiotoxic than the sodium salt formulations. Oncol Rep 1: 173-174, 1994
11. Fournet A, Gilard V, Malet-Martino M, et al: Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump. Cancer Chemother Pharmacol 46: 501-506, 2000